In hematologic malignancies, DDX43 is overexpressed in acute myeloid leukemia (AML), CML, multiple myeloma and a variety of malignant cell lines derived from B or T lymphocytic cells [8, 10–13]. Here, DDX43 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.